Provectus announced that the United States Patent and Trademark Office (USPTO) has allowed US patent application 16/688,319, Composition and Method for Treating Hematologic Cancers, covering the use of PV-10, a formulation of Provectus' immunogenic-small molecule and pharmaceutical-grade rose bengal sodium (RBS), for the treatment of hematologic diseases. In vivo data of mice with acute lymphoblastic leukemia receiving oral PV-10 showed increased survival compared to controls. This allowed patent application will be the first Provectus patent award in hematology from the USPTO.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.195 USD | -1.79% | +0.10% | +103.12% |
1st Jan change | Capi. | |
---|---|---|
+103.12% | 83.28M | |
-2.61% | 103B | |
+1.95% | 95.28B | |
+1.46% | 22.15B | |
-15.87% | 21.02B | |
-8.58% | 18.15B | |
-38.74% | 16.73B | |
-13.26% | 16.05B | |
+4.66% | 13.68B | |
+35.37% | 12.17B |
- Stock Market
- Equities
- PVCT Stock
- News Provectus Biopharmaceuticals, Inc.
- Provectus Biopharmaceuticals Announces Notice of Allowance of First U.S. Patent Application for Use of PV-10® Immunotherapy in Hematology